ArticleCancer research and treatment2018

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.

Tae Min Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.